Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Recognizing how persistent depressive disorder manifests and plays out in the lives of individuals is the first step in ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Among adults with chronic pain, people with certain types of pain are more vulnerable to depression and anxiety.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

Scientists at the National Center for Supercomputing Applications and the University of Illinois College of Medicine Peoria (UICOMP) were authors of a research paper published in the Journal of ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...